Depo-Provera is typically prescribed to prevent pregnancy; however, it is also used to treat endometriosis and as a palliative treatment of certain cancers.
Meningioma (new action)
Use of Depo-Provera has been associated with an increased risk of diagnosis, growth, or recurrence of spinal or brain meningioma. Meningiomas are a type of tumour that grow within the tissues that line the central nervous system, also known as meninges.
Siskinds LLP and Siskinds Desmeules are representing individuals in Canada who have been diagnosed with meningioma after long-term use of Depo-Provera. Siskinds LLP and Siskinds Desmeules are also representing estates of Canadians diagnosed with meningioma who subsequently passed away.
Bone mineral density loss (action terminated)
A settlement has been approved in class action litigation regarding Depo-Provera and bone mineral density loss and class members had until March 1, 2022 to file their claims. The settlement has now concluded and all approved claims have been paid.
We’re here to help
If you, or someone you know, used Depo Provera and was diagnosed with a spinal or brain meningioma, Siskinds may be able to help. Contact us by email: [email protected], call us toll-free at 1.800.461.6166, or complete the form at the bottom of this webpage, so that we can review your potential claim and determine if you may be eligible to seek compensation.
Developments
Meningioma (new action)
On October 29, 2024, Siskinds Desmeules filed an application for authorization to institute a class action before the Superior Court of Quebec, alleging liability as manufacturer of Pfizer for the safety defect of Depo-Provera in that there was a lack of sufficient indications as to the risks and dangers they involve or as to the means to avoid them, namely the risk of meningioma of the spine or brain.
You can view the application for authorization by clicking here.
The class action is in its early stage and has not yet been authorized by the court.
Bone mineral density loss (action terminated)
In 2021, the Superior Court of Quebec approved a settlement agreement for “Every person domiciled in Canada who used Depo-Provera and claims to be suffering or to have suffered a loss of bone mineral density owing to the use of Depo-Provera before May 31, 2010”
Eligible claimants had until March 1st, 2022 to file a claim form. All approved claims have been paid and the class action is now terminated.
FAQs
What is a class action?
A class action is a lawsuit that is brought by one or more person on behalf of a larger group of people whose claims share common legal and/or factual issues. Class actions provide a cost-effective way for groups of people with common interests to pursue a legal claim.
What does “certification” mean?
Certification (or Authorization in Quebec) is the motion where the court determines whether the action can properly be pursued as a class action. The court will consider factors such as whether the claims of the class members raise common legal and/or factual issues and whether a class action is the preferable method of pursuing the claims (as opposed to other methods, such as individual actions).
Do I have to pay anything to participate in the class action?
Class action lawyers are usually paid on a contingency basis. This means that class counsel are only paid if successful. Class counsel are paid a percentage of any settlement or court award. Class counsel fees are subject to court approval.
Who is covered by the Depo-Provera class action?
Meningioma (new action)
You are covered by the class action and could be a “class member” if you have been diagnosed with spinal or cerebral meningioma after using Depo-Provera for at least one year.
Bone Mineral Density Loss (action terminated)
Eligible claimants had until March 1st, 2022 to file a claim form. All approved claims have been paid and the class action is now terminated.
What should I do to protect my rights?
Meningioma (new action)
- Keep a record of medical expenses incurred — appointments not covered by your provincial health care provider, prescriptions, medical devices, etc.;
- Keep a record of all medical treatments, including the names and contact information of the health care provider (doctor, surgeon, physiotherapist etc.);
- If possible, keep a journal of symptoms and note any times when you are unable to attend work or school as a result of your symptoms.
- Register to updates by clicking on the Join button and complete the form to subscribe to our database to receive all updates and notices regarding this class action.
If you have not already done so already, you can contact Siskinds, so that we can help you obtain your relevant medical and pharmaceutical records. The more time goes by, the more difficult it may be to collect this information.
All personal information provided to Siskinds will be kept private and confidential.
Bone Mineral Density Loss (action terminated)
The Claims Filing Deadline is now expired; we will not be able to assist you if you used Depo-Provera.
I still have a question. Who should I contact?
Meningioma
If you have any other questions, please complete the Get in Touch form below, call us toll free at 1.877.735.3842 or email us at [email protected].
For information in French or to contact our Quebec office Siskinds Desmeules, call us at 418.694.2009 or toll free at 1.877.735.3842 or email us at [email protected].
Bone Mineral Density Loss (action terminated)
Eligible claimants had until March 1st, 2022 to file a claim form. All approved claims have been paid and the class action is now terminated. If necessary, you can contact the Claims Administrator at:
Collectiva, Class Action Services Inc.
2170 René-Lévesque Boulevard West, Suite 200
Montréal, QC H3H 2T8
Email: [email protected]
Toll-free: 1.888.667.5012
Documents
Meningioma (new action)
Application for authorization to institute a class action – October 29, 2024 (French Only)